Why is rofecoxib's stomach lining protection often compared to aspirin's?
Rofecoxib, a nonsteroidal anti-inflammatory drug (NSAID), was developed as a more selective cyclooxygenase-2 (COX-2) inhibitor, with less gastrointestinal (GI) toxicity compared to traditional NSAIDs like aspirin. [1]
What is the mechanism behind rofecoxib's stomach lining protection?
Rofecoxib selectively inhibits COX-2, an enzyme involved in inflammation and pain, while having minimal effect on COX-1, which is important for protecting the stomach lining. This selective inhibition reduces the production of prostaglandins, which can cause stomach lining damage, but also reduces the risk of GI side effects associated with traditional NSAIDs. [2]
How does rofecoxib compare to aspirin in terms of stomach lining protection?
Aspirin, a non-selective NSAID, inhibits both COX-1 and COX-2 enzymes, which can lead to a higher risk of GI side effects, including stomach ulcers and bleeding. In contrast, rofecoxib's selective COX-2 inhibition reduces the risk of GI toxicity, making it a more stomach-friendly option compared to aspirin. [3]
What happened to rofecoxib due to concerns about patent expiry and exclusivity?
Rofecoxib's patent expired in 2007, allowing generic versions of the drug to enter the market, which led to a significant drop in prices. This also raised concerns about patent-related issues and competition from generics. [4]
What is the current regulatory landscape for rofecoxib and aspirin?
In 2004, the US FDA approved rofecoxib for various indications, but in 2005, it removed rofecoxib from the market due to concerns about heart attack and stroke risks. Aspirin, on the other hand, remains widely available, although its GI side effects can be a concern for some patients.
Can biosimilars enter the market before patent expiry?
The patent expiration of rofecoxib has allowed biosimilar versions of the drug to enter the market, increasing competition and potentially disrupting the market for rofecoxib and its patent holder.
Sources:
[1] https://www.drugpatentwatch.com/Drug/ViewPatent.aspx?patentId=US-6242357
[2] https://en.wikipedia.org/wiki/Rofecoxib
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1447303/
[4] https://www.reuters.com/article/us-merck-vioxx-idUSTRE47G6P020071012